Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy

1. Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979; 3: 467–88. doi: 10.1111/j.1365-2559.1979.tb03029.x MartinezV AzzopardiJG Invasive lobular carcinoma of the breast: incidence and variants Histopathology 1979 3 467 88 10.1111/j.1365-2559.1979.tb03029.x Open DOISearch in Google Scholar

2. Yoder BJ, Wilkinson EJ, Massoli NA. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J 2007; 13: 172–79. doi: 10.1111/j.1524-4741.2007.00393.x YoderBJ WilkinsonEJ MassoliNA Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast Breast J 2007 13 172 79 10.1111/j.1524-4741.2007.00393.x Open DOISearch in Google Scholar

3. Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003; 63: 7167–75. PMID: 14612510 KorkolaJE DeVriesS FridlyandJ HwangES EstepAL ChenYY Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis Cancer Res 2003 63 7167 75 PMID: 14612510 Search in Google Scholar

4. Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 2002; 4: 5–8. doi: 10.1186/bcr416 Cleton-JansenAM E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 2002 4 5 8 10.1186/bcr416 Open DOISearch in Google Scholar

5. Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 2002; 87: 1105–11. doi: 10.1038/sj.bjc.6600556 CoradiniD PellizzaroC VeneroniS VenturaL DaidoneMG Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence Br J Cancer 2002 87 1105 11 10.1038/sj.bjc.6600556 Open DOISearch in Google Scholar

6. Toikkanen S, Pylkkanen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997; 76: 1234–40. doi: 10.1038/bjc.1997.540 ToikkanenS PylkkanenL JoensuuH Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma Br J Cancer 1997 76 1234 40 10.1038/bjc.1997.540 Open DOISearch in Google Scholar

7. Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 1994; 73: 1673–7. doi: 10.1002/1097-0142(19940315)73:6<1673::aid-cncr2820730620>3.0.co SilversteinMJ LewinskyBS WaismanJR GiersonED ColburnWJ SenofskyGM Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 1994 73 1673 7 10.1002/1097-0142(19940315)73:6<1673::aid-cncr2820730620>3.0.co Open DOISearch in Google Scholar

8. Molland JG, Donnellan M, Janu NC, Carmalt HL, Kennedy CW, Gillet DJ. Infiltrating lobular carcinoma – a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 2004; 13: 389–96. doi: 10.1016/j.breast.2004.03.004 MollandJG DonnellanM JanuNC CarmaltHL KennedyCW GilletDJ Infiltrating lobular carcinoma – a comparison of diagnosis, management and outcome with infiltrating duct carcinoma Breast 2004 13 389 96 10.1016/j.breast.2004.03.004 Open DOISearch in Google Scholar

9. Ashikari R, Huvos AG, Urban JA, Robbins GF. Infiltrating lobular carcinoma of the breast. Cancer 1973; 31: 110–6. doi: 10.1002/1097-0142(197301)31:1<110::aid-cncr2820310115>3.0.co;2-v AshikariR HuvosAG UrbanJA RobbinsGF Infiltrating lobular carcinoma of the breast Cancer 1973 31 110 6 10.1002/1097-0142(197301)31:1<110::aid-cncr2820310115>3.0.co;2-v Open DOISearch in Google Scholar

10. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, Bouita L, Cohen-Solal C, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncology 2006; 17: 1228–33. doi: 10.1093/annonc/mdl114 Tubiana-HulinM StevensD LasryS GuinebretiereJM BouitaL Cohen-SolalC Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution Ann Oncology 2006 17 1228 33 10.1093/annonc/mdl114 Open DOISearch in Google Scholar

11. Cristofanilli M, Gonzales-Angulo A, Sneige N, Kau S-W, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005; 23: 41–8. doi: 10.1200/JCO.2005.03.111 CristofanilliM Gonzales-AnguloA SneigeN KauS-W BroglioK TheriaultRL Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes J Clin Oncol 2005 23 41 8 10.1200/JCO.2005.03.111 Open DOISearch in Google Scholar

12. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004; 40: 342–51. doi: 10.1016/j.ejca.2003.08.015 MathieuMC RouzierR Llombart-CussacA SiderisL KoscielnyS TravagliJP The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile Eur J Cancer 2004 40 342 51 10.1016/j.ejca.2003.08.015 Open DOISearch in Google Scholar

13. Du Toit RS, Locker AP, Ellis IQ, Elston CW, Nicholson RI, Robertson JF, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 1991; 17: 251–7. PMID: 1646127 Du ToitRS LockerAP EllisIQ ElstonCW NicholsonRI RobertsonJF An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast Eur J Surg Oncol 1991 17 251 7 PMID: 1646127 Search in Google Scholar

14. Rakha EA, EL-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008; 44: 73–83. doi: 10.1016/j.ejca.2007.10.009 RakhaEA EL-SayedME PoweDG GreenAR HabashyH GraingeMJ Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes Eur J Cancer 2008 44 73 83 10.1016/j.ejca.2007.10.009 Open DOISearch in Google Scholar

15. Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, et al. Genomic characterization of primary invasive lobular breast cancer. J Clinical Oncol 2016; 34: 1872–81. doi: 10.1200/JCO.2015.64.0334 DesmedtC ZoppoliG GundemG PruneriG LarsimontD ForniliM Genomic characterization of primary invasive lobular breast cancer J Clinical Oncol 2016 34 1872 81 10.1200/JCO.2015.64.0334 Open DOISearch in Google Scholar

16. Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, et al. Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data. J Clin Oncol 2018; 36: 981–90. doi: 10.1200/JCO.2017.74.830 ZardavasD Te MarveldeL MilneRL FumagalliD FountzilasG KotoulaV Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data J Clin Oncol 2018 36 981 90 10.1200/JCO.2017.74.830 Open DOISearch in Google Scholar

17. Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial. J Clin Oncol 2015; 33: 2772–9. doi: 10.1200/JCO.2015.60.8133 Metzger FilhoO Giobbie-HurderA MallonE GustersonB VialeG WinerEP Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial J Clin Oncol 2015 33 2772 9 10.1200/JCO.2015.60.8133 Open DOISearch in Google Scholar

18. Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell”Orto P, et al. Association of somatic driver alterations with prognosis in postmenopausal, hormone receptor-positive, HER2-negative early breast cancer: a secondary analysis of the BIG 1–98 randomized clinical trial. JAMA Oncol 2018; 4: 1335–43. doi: 10.1001/jamaoncol.2018.1778 LuenSJ AsherR LeeCK SavasP KammlerR Dell”OrtoP Association of somatic driver alterations with prognosis in postmenopausal, hormone receptor-positive, HER2-negative early breast cancer: a secondary analysis of the BIG 1–98 randomized clinical trial JAMA Oncol 2018 4 1335 43 10.1001/jamaoncol.2018.1778 Open DOISearch in Google Scholar

19. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histopathological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991; 19: 403–10. doi: 10.1111/j.1365-2559.1991.tb00229.x ElstonCW EllisIO Pathological prognostic factors in breast cancer. I. The value of histopathological grade in breast cancer: experience from a large study with long-term follow up Histopathology 1991 19 403 10 10.1111/j.1365-2559.1991.tb00229.x Open DOISearch in Google Scholar

20. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134: e48–72. doi: 10.1200/JCO.2009.25.6529 HammondME HayesDF DowsettM AllredDC HagertyKL BadveS American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer Arch Pathol Lab Med 2010 134 e48 72 10.1200/JCO.2009.25.6529 Open DOISearch in Google Scholar

21. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor-2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997–4013. doi: 10.1200/JCO.2013.50.9984 WolffAC HammondME HicksDG DowsettM McShaneLM AllisonKH Recommendations for human epidermal growth factor receptor-2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 2013 31 3997 4013 10.1200/JCO.2013.50.9984 Open DOISearch in Google Scholar

22. Dowsett M, O Nielsen T, A”Hern R, BartletT J, Coombes RC, Cuzick J, et al. Assessment of Ki-67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103: 1656–64. doi: 10.1093/jnci/djr393 DowsettM O NielsenT A”HernR BartletTJ CoombesRC CuzickJ Assessment of Ki-67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer Working Group J Natl Cancer Inst 2011 103 1656 64 10.1093/jnci/djr393 Open DOISearch in Google Scholar

23. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259–71. doi: 10.1093/annonc/mdu450 SalgadoR DenkertC DemariaS SirtaineN KlauschenF PruneriG The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 Ann Oncol 2015 26 259 71 10.1093/annonc/mdu450 Open DOISearch in Google Scholar

24. Samuels Y, Wang Z, Bardeli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutation of the PIK3CA gene in human cancers. Science 2004; 304: 554. doi: 10.1126/science.1096502 SamuelsY WangZ BardeliA SillimanN PtakJ SzaboS High frequency of mutation of the PIK3CA gene in human cancers Science 2004 304 554 10.1126/science.1096502 Open DOISearch in Google Scholar

25. Pramod N, Nigam A, Basree M, Mawalkar R, Mehra S, Shinde N, et al. Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer. Oncologist 2021; 26: e943–53. doi: 10.1002/onco.13734 PramodN NigamA BasreeM MawalkarR MehraS ShindeN Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer Oncologist 2021 26 e943 53 10.1002/onco.13734 Open DOISearch in Google Scholar

26. Johansson A, Yu NY, Iftimi A, Tobin NP, vant Veer L, Nordenskjold B, et al. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature. Int J Cancer 2022; 150: 2072–82. doi: 10.1002/ijc.33969 JohanssonA YuNY IftimiA TobinNP vant VeerL NordenskjoldB Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature Int J Cancer 2022 150 2072 82 10.1002/ijc.33969 Open DOISearch in Google Scholar

27. Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, et al. The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun 2018; 9: 3476. doi: 10.1038/s41467-018-05914-x GriffithOL SpiesNC AnuragM GriffithM LuoJ TuD The prognostic effects of somatic mutations in ER-positive breast cancer Nat Commun 2018 9 3476 10.1038/s41467-018-05914-x Open DOISearch in Google Scholar

28. McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res 2021; 23: 6. doi: 10.1186/s13058-020-01384-6 McCart ReedAE KalinowskiL SimpsonPT LakhaniSR Invasive lobular carcinoma of the breast: the increasing importance of this special subtype Breast Cancer Res 2021 23 6 10.1186/s13058-020-01384-6 Open DOISearch in Google Scholar

29. McCart Reed AE, Lal S, Kutasovic JR, Wockner L, Robertson A, de Luca XM, et al. LobSig is a multigene predictor of outcome in invasive lobular carcinoma. NPJ Breast Cancer 2019; 5: 18. doi: 10.1038/s41523-019-0113-y McCart ReedAE LalS KutasovicJR WocknerL RobertsonA de LucaXM LobSig is a multigene predictor of outcome in invasive lobular carcinoma NPJ Breast Cancer 2019 5 18 10.1038/s41523-019-0113-y Open DOISearch in Google Scholar

30. Metzger FO, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial. J Clin Oncol 2015; 33: 2772–79. doi: 10.1200/JCO.2015.60.813 MetzgerFO Giobbie-HurderA MallonE GustersonB VialeG WinerEP Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial J Clin Oncol 2015 33 2772 79 10.1200/JCO.2015.60.813 Open DOISearch in Google Scholar

31. Lopez-Knowles E, Segal CV, Gao Q, Garcia-Murillas I, Turner NC, Smith I, et al. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Res 2014; 16: R68. doi: 10.1186/bcr3683 Lopez-KnowlesE SegalCV GaoQ Garcia-MurillasI TurnerNC SmithI Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition Breast Cancer Res 2014 16 R68 10.1186/bcr3683 Open DOISearch in Google Scholar

32. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbeck V, Larsimont D, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010; 107: 10208–13. doi: 10.1073/pnas.0907011107 LoiS Haibe-KainsB MajjajS LallemandF DurbeckV LarsimontD PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer Proc Natl Acad Sci USA 2010 107 10208 13 10.1073/pnas.0907011107 Open DOISearch in Google Scholar

33. Whyte DB, Holbeck SL. Correlation of PIK3CA mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 2006; 340: 469–75. doi: 10.1016/j.bbrc.2005.12.025 WhyteDB HolbeckSL Correlation of PIK3CA mutations with gene expression and drug sensitivity in NCI-60 cell lines Biochem Biophys Res Commun 2006 340 469 75 10.1016/j.bbrc.2005.12.025 Open DOISearch in Google Scholar